Craciun M, et al. - In this prospective study, researchers tried to present the results over a 9-year period of the active management protocol for bothersome overactive bladder (OAB) symptoms using abobotulinumtoxinA (Dysport). Reviewed data from consecutive patients with OAB symptoms due to urodynamically-proven idiopathic detrusor overactivity who had failed pharmacotherapy with maximum dose and bladder drill. Under general anaesthesia, 250 units of abobotulinumtoxinA were injected. The results of 299 treatments were reviewed in 170 patients. Due to high postvoid residuals, de-novo self-catheterization was required in 18.2% of cases. For patients with refractory OAB symptoms, the use of abobotulinumtoxinA is a safe and highly effective treatment option. The data show similar results in terms of improvement of symptom score and self-catheterization rates to onabotulinumtoxinA.